1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Implementation Science to Optimize HIV Prevention and Treatment is sponsored by National Institutes of Health (NIH) - National Institute of Nursing Research (NINR), National Institute on Drug Abuse (NIDA), NIH Office of AIDS Research (OAR). Encourages implementation research to advance innovative strategies to deliver biomedical prevention and treatment options toward ending the HIV epidemic.
This includes integrating evidence-based interventions for HIV prevention and treatment into real-world settings.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Researchers and institutions focused on implementation science relevant to HIV prevention and treatment. Applications should include clear implementation outcomes and use rigorous methods. Confirm the full requirements in the official notice before applying.
Applications for Implementation Science to Optimize HIV Prevention and Treatment are due December 2, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Implementation Science to Optimize HIV Prevention and Treatment is funded by National Institutes of Health (NIH) - National Institute of Nursing Research (NINR), National Institute on Drug Abuse (NIDA), NIH Office of AIDS Research (OAR). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articlePA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read article